OriGene Logo
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
Home Antibody All anti-BCL9L antibodies

Anti-BCL9L Antibody Polyclonal


Specifications Citations Customer Reviews Product Documents
SKU Description Amount Price Availability*  
TA320156 Rabbit Polyclonal Bcl9L Antibody 100ug $325 3-7 Days
LC405481 BCL9L HEK293T cell transient overexpression lysate (as WB positive control) 20ug $50 In Stock
Add to Shopping Cart

OriGene Data

ImmunogenBcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L.
Clone NamePolyclonal IsotypeIgG
Species ReactivityHuman, Mouse, Rat Concentration1ug/ul
Guaranteed Application *WB, IF Suggested DilutionsWB: 1 ug/mL, ICC: 10 ug/mL
BufferBcl9L Antibody is supplied in PBS containing 0.02% sodium azide.
Purification Bcl9L Antibody is affinity chromatography purified via peptide column.

Reference Data

Target NameB-cell CLL/lymphoma 9-like
Alternative NameBCL9-2|DLNB11
Database LinkNP_872363
Entrez Gene 283149 Human
Entrez Gene 80288 Mouse
Entrez Gene 300673 Rat
FunctionBcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.
Related Pathway

* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.

WB Image
Western blot analysis of Bcl9L in HeLa cell lysate with Bcl9L antibody at 1 ug/mL in (A) the absence and (B) the presence of blocking peptide.

IF Image
Immunocytochemistry of Bcl9L in HeLa cells with Bcl9L antibody at 10 ug/mL.


Inc 5000 Healthcare Company

Notice to Non-US Customers

ExclaimationWeb price and delivery time are for direct sales only.

Non-US customers are encouraged to contact our dedicated distributor network for quotes and streamlined ordering/delivery support.